The market for regenerative biologics — amniotic tissue, umbilical cord products, exosomes, and related HCT/P products — has expanded significantly over the past five years. So has regulatory scrutiny. The FDA has issued warning letters, conducted facility inspections, and taken enforcement action against distributors and clinics that were not operating within the required framework.
If you are considering adding biologics to your clinical menu, or if you are currently ordering biologics and want to confirm your sourcing is compliant, this guide covers the regulatory foundation, what documentation to require from your supplier, and the practical steps to set up a compliant program.
The Regulatory Framework: FDA 21 CFR Part 1271
Human cells, tissues, and cellular and tissue-based products (HCT/Ps) are regulated under FDA 21 CFR Part 1271. This regulatory framework governs how HCT/Ps must be manufactured, tested, labeled, stored, and distributed.
Under 361 of the Public Health Service Act and 21 CFR Part 1271, HCT/Ps that meet specific criteria — minimal manipulation, homologous use, not combined with a drug or device, not having a systemic effect — are regulated as HCT/P products rather than as biologics drug products. This is the regulatory category under which amniotic, umbilical cord, and many exosome products are distributed.
What 'Minimal Manipulation' Means
Minimal manipulation means the processing does not alter the relevant biological characteristics of the tissue. Products that undergo only cutting, grinding, shaping, or similar processing without chemical treatment that would alter cellular or structural characteristics generally qualify. Products processed with growth factors, chemical expansion, or significant cellular selection may not qualify.
What 'Homologous Use' Means
Homologous use means the product performs the same basic function in the recipient as it did in the donor. Amniotic membrane used to support tissue covering and protective functions in wound care is an example of homologous use. Amniotic membrane repurposed for orthopedic joint injection for regenerative purposes is closer to a non-homologous use and may trigger different regulatory requirements.
What Documentation to Require from Your Supplier
Every compliant biologics supplier should provide — without you having to ask — the following documentation for every product:
Certificate of Analysis (COA)
The COA documents testing results for sterility, identity, potency (where applicable), and relevant quality attributes. The testing should be performed by an independent, accredited laboratory. A COA signed only by the manufacturer with no independent third-party testing is a compliance red flag.
Certificate of Conformance
Confirms that the specific lot was manufactured in conformance with applicable regulations and the manufacturer's quality management system. Should include lot number, manufacturing date, expiration date, and the specific CFR sections or standards the product was manufactured under.
Donor Screening Documentation
21 CFR Part 1271 requires donor screening and testing for relevant communicable disease agents. Your supplier should be able to confirm that donor screening was performed per these requirements, even if the specific screening records are not shared (they typically are not shared for privacy reasons, but a summary confirming compliance should be available).
Chain-of-Custody Records
From tissue collection through processing, storage, and shipping to your clinic, the chain of custody should be traceable. For your clinic's records, you should document the lot number, supplier, receipt date, storage conditions at receipt, and which patients received which lot.
Red Flags to Avoid
The following practices from a biologics supplier should prompt immediate reconsideration:
Marketing claims that products treat, cure, or heal specific conditions. Inability to provide lot-specific COA and Certificate of Conformance. No disclosed CLIA certification or AATB accreditation for the manufacturing facility. Distribution to non-licensed individuals or without NPI verification. Pricing significantly below market — very low cost often reflects quality or sourcing shortcuts.
Setting Up a Compliant Clinic Protocol
Storage
Most amniotic and umbilical cord products are cryopreserved and require specific thaw protocols. Confirm storage requirements with your supplier and ensure your facility has appropriate freezer equipment and temperature monitoring.
Patient Selection and Informed Consent
Patients receiving HCT/P biologics should provide informed consent that describes the product type, the intended use, the regulatory status (HCT/P under 21 CFR Part 1271, not FDA-approved as a drug for specific indications), and the physician's clinical rationale.
Record-Keeping
FDA guidance recommends that clinics maintain records linking specific product lots to specific patients, including lot number, supplier, date of administration, and anatomical site. These records are your protection in the event of a product recall or adverse event investigation.
Why Sourcing from a Compliant Distributor Matters for Your License
State medical boards have increasingly coordinated with FDA on biologic-related enforcement actions. A clinic that purchases and administers a product from a non-compliant supplier — even without knowing the supplier was non-compliant — can face state licensing consequences in addition to FDA enforcement. The documentation and supplier vetting process is not just a regulatory exercise; it is direct protection for your license.
Golden Lotus Labs distributes FDA-compliant amniotic, umbilical cord, and exosome biologics to licensed providers. Certificate of conformance, COA, and full chain-of-custody documentation are included with every order. Inquire about our partner program for access to our complete biologics catalog.